Heterocyclic Derivatives Selective Nav1.7 Nav1.8 Blockers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium channel blockers for pain management, such as lidocaine, have limited efficacy and cause side effects due to non-subtype selective inhibition, particularly affecting Nav1.5 channels, which are not ideal for targeting Nav1.7 and Nav1.8 channels involved in pain pathways.
Innovation Solution
Development of heterocyclic derivatives that selectively block Nav1.7 and Nav1.8 channels with higher affinity than Nav1.5 channels, possessing favorable pharmacokinetic properties, stability, and reduced toxicity, allowing for effective pain treatment with improved side-effect profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sodium channel blockers (e.g., lidocaine) are used for pain management, then pain relief is achieved, but side effects occur due to non-subtype selective inhibition of Nav1.5 channels
Solution Approach 1:
The patent applies local quality by designing heterocyclic derivatives with specific molecular structures (formula I) that exhibit differential affinity for different sodium channel subtypes. The compounds are engineered to selectively target Nav1.7 and Nav1.8 channels while minimizing interaction with Nav1.5 channels, thereby providing localized therapeutic effect at pain pathways without systemic harmful effects on cardiac tissue.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of sodium channel blockers through heterocyclic derivatization. Specific substituents (R1-R6 groups) are varied to optimize binding affinity for Nav1.7/Nav1.8 versus Nav1.5 channels. This structural parameter optimization results in compounds with improved selectivity ratios, reducing side effects while maintaining analgesic efficacy.
2Adaptability or versatility
If non-subtype selective sodium channel blockers are used, then broad channel inhibition is achieved, but therapeutic index is reduced due to lack of specificity for Nav1.7 and Nav1.8
Solution Approach 1:
The patent applies segmentation by dividing the sodium channel blocking activity into subtype-specific components. Instead of a single broad-spectrum blocker, the invention develops compounds that selectively inhibit specific subtypes (Nav1.7 and Nav1.8) responsible for pain transmission, separating the therapeutic function from harmful off-target effects.
Solution Approach 2:
The heterocyclic derivatives exhibit local quality through their selective binding characteristics. The molecular structure (formula I with specific R1-R6 substituents) creates a pharmacophore that preferentially interacts with Nav1.7 and Nav1.8 channels in peripheral nerves, providing localized therapeutic action without widespread channel inhibition.
3Reliability
If high potency Nav1.7 and Nav1.8 blockers are developed, then pain selectivity is improved, but drug development complexity increases
Solution Approach 1:
The patent applies universality by creating a heterocyclic derivative framework (formula I) that can be systematically modified to achieve multiple objectives: Nav1.7/Nav1.8 selectivity, appropriate pharmacokinetic properties, and therapeutic efficacy. The common core structure serves multiple functions while substitutable groups (R1-R6) allow optimization for specific indications.
Data Source
AI summary
The present invention relates to heterocyclic derivatives which have blocking activities of voltage gated sodium channels as the Nav1.7 and Nav1.8 channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.